Navigation Links
MEDRAD Builds on Success of P3T Cardiac CT Injection Software
Date:11/24/2008

WARRENDALE, Pa., Nov. 24 /PRNewswire/ -- Encouraged by successful results from use of its patented personalized patient protocol software P3T(TM) Cardiac, MEDRAD, Inc. is working on advancing the P3T family of products for clinical applications beyond Cardiac CT. MEDRAD will demonstrate some of these potential advances at its RSNA Booth 2815 Hall A, South Building.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

Personalized patient injection protocols are showing promise, according to a recent University of Pittsburgh Medical Center (UPMC) study(1) which documented that contrast injection protocols personalized to patient-specific parameters of its test group resulted in a higher percentage of exams that could be classified as "diagnostic, without limitations" to rule out pulmonary embolism than resulted from non-personalized standard injection protocols.(2) A diagnostic exam without limitations is the type that is most desired by radiologists. The personalized patient protocols provided better contrast enhancement of the pulmonary arteries in the study group as well.(2) Researchers presented the study results in a scientific poster at a meeting of the Society of Thoracic Radiology earlier this year. Copies of the study will be available at MEDRAD's booth at the RSNA 2008 exhibition in Chicago, November 30 through December 5.

Joan Lacomis, radiologist at UPMC and co-author of the UPMC study, said, "Achieving a diagnostic CT image for pulmonary embolism, without limitations, helps the hospital and emergency department in a number of important ways -- with efficiency, patient care, and cost savings. Achieving high quality images for a higher percentage of studies multiplies these benefits and our research indicates that personalizing the contrast injection protocol to patient-specific parameters is a promising approach."

Pulmonary Embolism (PE) is a sudden blood clot or blockage in a lung artery and is a serious condition. At least 100,000 cases of PE occur each year in the United States, according to the National Institutes of Health. PE is the third most common cause of death in hospitalized patients, and if left untreated, kills about 30 percent of patients who have it. Most of those who die do so within the first few hours of the event. CT imaging is often used in the emergency department setting to quickly identify the presence of life-threatening disorders like PE, making efficiency important in quickly and accurately diagnosing the condition. CT has a high specificity and sensitivity in ruling out PE, and researchers in a 2005 meta-analysis (JAMA 2005; 293:2012-17) found that the negative predictive value of a CT angiography of the pulmonary arteries was 99.4%.

MEDRAD, Inc. is a worldwide leading provider of medical devices and services that enable and enhance imaging and therapeutic procedures of the human body. For diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. The company also offers products used in vascular intervention. MEDRAD's total 2007 revenues were $525 million. In 2003, MEDRAD received the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at http://www.medrad.com.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, Inc. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

(1) Lacomis, J; et al. "A Clinical Evaluation of the MEDRAD SmartFlow Power Injector Software System for Contrast Delivery in Patients Suspected of Pulmonary Embolism Undergoing Chest CTA". Society of Thoracic Radiology. http://www.thoracicrad.org/meetings/str2008/Syllabus/additional/posters.pdf. March 2008.

(2) P3T Cardiac indicated for CT Pulmonary Angiography is pending FDA clearance [510(k) pending].


'/>"/>
SOURCE MEDRAD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
2. MEDRAD Plant Named IndustryWeek Magazine Award Finalist
3. MEDRAD Mobile MR Injector Meets Challenges of MR Trailers
4. MEDRAD(R) Revenues Grow 10 Percent in 2007
5. MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery
6. MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System
7. MEDRAD Multi Vendor Service Forms Alliance with Wetsco
8. Fat Builds Up in Hearts Before Diabetes Onset
9. SYMX Builds on Top of New Microsoft Technologies to Offer Hospitals Real-Time Business and Patient Safety Solutions Using RFID Data
10. Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience
11. Biotechnology Builds a New Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , ... May 06, 2016 , ... The International ... on the north end of the island close to the town famous for its ... 10th 2016. , “We continue to have an amazing experience in Greece, we ...
(Date:5/6/2016)... ... 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a ... in the Bible about helping to stop cancer. Yisrayl says there are too many suffering ... the health and science industries will pay close attention and take action. The Pastor says ...
(Date:5/6/2016)... OR (PRWEB) , ... May 06, 2016 , ... This ... but for women everywhere. The 17th annual National Women’s Health Week takes ... Office on Women’s Health are combining forces to empower women to make their health ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. co-founder, ... BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid Services ... Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross and ...
(Date:5/5/2016)... ... 2016 , ... Pivot Point Consulting achieved the ... KLAS Performance Report, Epic Consulting 2016 - Which Firms Provide Breadth, Depth, ... services for electronic health record (EHR) solutions from Epic Systems Corporation . ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
Breaking Medicine Technology: